In addition, it is able to act synergistically with doxorubicin, a chemotherapeutic drug that activates the IKK complex through protein kinase C. From these studies, IKK inhibitors show promise as therapeutic agents for targeting aberrant NF-κB activation in canine and human NHL, possibly reducing acquired chemoresistance thus leading to enhanced patient survival. This evidence concerns the gene NFKB1 and non-Hodgkin lymphoma.